
Nyxoah SA (NYXH) Stock Forecast & Price Target
Nyxoah SA (NYXH) Analyst Ratings
Bulls say
Nyxoah is poised for significant growth in the sleep-disordered breathing solutions market due to its innovative Genio system and recent strong financial performance, including a 499% year-over-year revenue increase in Q1. With a promising FY26 revenue guidance above analyst expectations and a successful U.S. commercial launch, the company is well-positioned to capture market share through 2026. Additionally, upcoming catalysts such as the ACCCESS study results in June/July 2026 and positive updates on personnel are potential drivers for investor confidence. However, risks include standard adoption challenges, potential cash-burn and regulatory risks associated with the ACCCESS study.
Bears say
Nyxoah is a relatively new company in the medical technology industry, and while they have shown signs of growth in their sales force and revenue projections, their success is contingent on the completion of their ACCCESS study in late June 2026/early July 2026 to potentially obtain label expansion by early-2027. Without this milestone, their outlook may not be as optimistic as projected.
This aggregate rating is based on analysts' research of Nyxoah SA and is not a guaranteed prediction by Public.com or investment advice.
Nyxoah SA (NYXH) Analyst Forecast & Price Prediction
Start investing in Nyxoah SA (NYXH)
Order type
Buy in
Order amount
Est. shares
0 shares